(Q38285619)

1 September 2017

1 reference

title

Treatment of IBD: where we are and where we are going (English)

1 reference

1 September 2017

Charles N Bernstein

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

9 December 2014

1 reference

The American Journal of Gastroenterology

1 September 2017

published in

1 reference

1 September 2017

volume

110

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

114-126

1 reference

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Is there still a role for thiopurines in Crohn's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Infectious and malignant complications of TNF inhibitor therapy in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Use of exclusive enteral nutrition in adults with Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Effects of enteral nutrition on Crohn's disease: clues to the impact of diet on disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Information needs and preferences of recently diagnosed patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Diet and inflammatory bowel disease: review of patient-targeted recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Gut microbiota composition correlates with diet and health in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Therapeutic potential of fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Curbing our enthusiasm for fecal transplantation in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Systematic review: the efficacy of herbal therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Common symptoms and stressors among individuals with inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

A prospective population-based study of triggers of symptomatic flares in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Narcotic use for inflammatory bowel disease and risk factors during hospitalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Cannabis use amongst patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Loperamide improves anal sphincter function and continence after restorative proctocolectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Quantification of the placebo response in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

The placebo effect for gastroenterology: tool or torment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.357

The constipating effect of diphenoxylate (Retardinr) in ulcerative colitis. A double-blind controlled trial

21 January 2018

1 reference

12 December 2020

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

1 reference

12 December 2020

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

1 reference

12 December 2020

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

1 reference

12 December 2020

Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission

1 reference

12 December 2020

Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

1 reference

12 December 2020

Loperamide oxide for the treatment of chronic diarrhoea in Crohn's disease

1 reference

12 December 2020

Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews

1 reference

12 December 2020

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis

1 reference

12 December 2020

Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway

1 reference

12 December 2020

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

12 December 2020

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

1 reference

12 December 2020

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

12 December 2020

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience

1 reference

12 December 2020

Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study.

1 reference

12 December 2020

Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease

1 reference

12 December 2020

A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection.

1 reference

12 December 2020

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

12 December 2020

Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study

1 reference

12 December 2020

Identifiers

DOI

10.1038/AJG.2014.357

1 reference

1 September 2017

1 reference